Who are we?
- BioRelix can advance the fight against drug resistant microbes by attacking novel targets with novel drugs. We have a robust in-house antimicrobial discovery platform focused on Riboswitches. RiboSwitches are the first new major class of targets for antibacterial drug discovery in decades
There are no activities to display at this time